Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988753 | 1.00 | TP53 (0.48) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| Nitrogen SCHEMBL28738062 | 0.95 | TP53 (0.46) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL74396 | 0.89 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2200767 | 0.89 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL244740 | 0.89 | — | — | |
| SCHEMBL2948892 | 0.89 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL6271997 | 0.87 | — | — | |
| SCHEMBL8610883 | 0.87 | TP53 (0.54) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| Methyl Alcohol SCHEMBL27845135 | 0.87 | TP53 (0.54) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL15746423 | 0.86 | CHRNB2 (0.45) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285459-B | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117285459-A | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-117285459-B | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117285459-A | Preparation method of small molecule kinase inhibitor compound | 上海美迪西生物医药股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-04-20 | — | — | US | disclosed |
| JP-2022108829-A | METHOD FOR PRODUCING (+)-TRANS-4-(1-AMINOETHYL)-1-(4-PYRIDYLCARBAMOYL)CYCLOHEXANE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDUCT THEREOF AND PRODUCTION INTERMADIATE THEREOF | 大内新興化学工業株式会社 | 2022-07-27 | — | — | JP | disclosed |
| EP-2706852-B1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2863915-B1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2884982-B1 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| WO-2012154518-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120108812-A1 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | OSI PHARMACEUTICALS ,INC. | 2012-05-03 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TP53 4167/4885SMN1; SMN2 1248/4885CHRNB2 164/4885 |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | ULK1, ULK2, ULK3 | TP53 57/4885SMN1; SMN2 3952/4885CHRNB2 4688/4885 |
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | TP53 4562/4885SMN1; SMN2 4639/4885CHRNB2 3904/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | TP53 107/4885SMN1; SMN2 804/4885CHRNB2 4799/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | TP53 4249/4885SMN1; SMN2 4150/4885CHRNB2 296/4885 |
| US-20120108812-A1 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | ALKBH5, NT5C, CYP4Z1 | TP53 3736/4885SMN1; SMN2 3532/4885CHRNB2 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.